Divi's Laboratories logo

DIVISLAB - Divi's Laboratories Share Price

₹3718.45 -61.2  -1.6%

Last Trade - 13/04/21

Large Cap
Market Cap £9.58bn
Enterprise Value £9.58bn
Revenue £523.6m
Position in Universe 41st / 3106
Unlock DIVISLAB Revenue
Relative Strength (%)
1m +10.4%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -5.02%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
31,149 38,049 41,063 39,128 49,463 53,944 68,659 82,620 +11.6%
+10.6 +31.7 -6.1 -16.9 +53.6 +1.9 +42.1 +22.1
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, Divi'sLaboratories Ltd revenues increased 29% to RS51.81B. Netincome increased 50% to RS14.82B. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Net income benefitedfrom Finance costs decrease of 88% to RS6.6M (expense).Basic Earnings per Share excluding Extraordinary Itemsincreased from RS37.23 to RS55.84.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for DIVISLAB
Graphical History


DIVISLAB Revenue Unlock DIVISLAB Revenue

Net Income

DIVISLAB Net Income Unlock DIVISLAB Revenue

Normalised EPS

DIVISLAB Normalised EPS Unlock DIVISLAB Revenue

PE Ratio Range

DIVISLAB PE Ratio Range Unlock DIVISLAB Revenue

Dividend Yield Range

DIVISLAB Dividend Yield Range Unlock DIVISLAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
DIVISLAB EPS Forecasts Unlock DIVISLAB Revenue
Profile Summary

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. The Company's geographical segments include India (Sales to customers within India) and other countries (Sales to customers outside India). Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids. It is also involved in developing alternate, non-infringing processes for APIs, for the inventors to manage late life cycle and generic drug manufacturers. The Company develops carotenoids, such as Apocarotenal, Betacarotene, Lycopene, Astaxanthin and Canthaxanthin. It manufactures tert-butoxycarbonyl (BOC), Fluorenylmethyloxycarbonyl (FMOC) and Carboxybenzyl (CBZ) protected amino acids. It manufactures ligands, such as binol and binap. The Company exports its products to European and the American countries. Its manufacturing and research and development facilities are located in the State of Andhra Pradesh and Telangana in India.

Last Annual March 31st, 2020
Last Interim January 1st, 1970
Incorporated October 12, 1990
Public Since June 25, 1905
No. of Shareholders: 101,169
No. of Employees: 13,884
Sector Healthcare
Industry Pharmaceuticals
Index S&P BSE 100 , Nifty 50 ,
Exchange National Stock Exchange of India
Shares in Issue 265,450,000
Free Float (0.0%)
Eligible for
DIVISLAB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for DIVISLAB
Upcoming Events for DIVISLAB
Friday 4th June, 2021 Estimate
Q4 2021 Divi's Laboratories Ltd Earnings Release
Friday 6th August, 2021 Estimate
Q1 2022 Divi's Laboratories Ltd Earnings Release
Frequently Asked Questions for Divi's Laboratories
What is the Divi's Laboratories share price?

As of 13/04/21, shares in Divi's Laboratories are trading at ₹3718.45, giving the company a market capitalisation of £9.58bn. This share price information is delayed by 15 minutes.

How has the Divi's Laboratories share price performed this year?

Shares in Divi's Laboratories are currently trading at ₹3718.45 and the price has moved by 58.83% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Divi's Laboratories price has moved by -0.12% over the past year.

What are the analyst and broker recommendations for Divi's Laboratories?

Of the analysts with advisory recommendations for Divi's Laboratories, there are there are currently 7 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Divi's Laboratories is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Divi's Laboratories next release its financial results?

It is not known when Divi's Laboratories will next release financial results.

What is the Divi's Laboratories dividend yield?

Divi's Laboratories does not currently pay a dividend.

Does Divi's Laboratories pay a dividend?

Divi's Laboratories does not currently pay a dividend.

When does Divi's Laboratories next pay dividends?

Divi's Laboratories does not currently pay a dividend.

How do I buy Divi's Laboratories shares?

To buy shares in Divi's Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Divi's Laboratories?

Shares in Divi's Laboratories are currently trading at ₹3718.45, giving the company a market capitalisation of £9.58bn.

Where are Divi's Laboratories shares listed? Where are Divi's Laboratories shares listed?

Here are the trading details for Divi's Laboratories:

Country of listing: India
Exchange: NSI
Ticker Symbol: DIVISLAB
What kind of share is Divi's Laboratories?

Based on an overall assessment of its quality, value and momentum, Divi's Laboratories is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Divi's Laboratories share price forecast 2021?

Shares in Divi's Laboratories are currently priced at ₹3718.45. At that level they are trading at 10.75% discount to the analyst consensus target price of 0.00.

Analysts covering Divi's Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 73.838 for the next financial year.

How can I tell whether the Divi's Laboratories share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Divi's Laboratories. Over the past six months, the relative strength of its shares against the market has been -3.25%. At the current price of ₹3718.45, shares in Divi's Laboratories are trading at 13.58% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Divi's Laboratories PE Ratio?

The Divi's Laboratories PE ratio based on its reported earnings over the past 12 months is 71.58. The shares are currently trading at ₹3718.45.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Divi's Laboratories?

Divi's Laboratories's management team is headed by:

Murali Divi - CHM
N. Ramana - EDR
Madhusudana Divi - EDR
Kiran Divi - CEO
G. Suresh Kumar - NID
L. Kishore Babu - CFO
Ravipati Rao - NID
Ramesh Nimmagadda - NEC
Nilima Motaparti - EDR
S. Ganapaty - NID
K. V. Chowdary - NID
M. Satish Choudhury - SEC
Who are the major shareholders of Divi's Laboratories?

Here are the top five shareholders of Divi's Laboratories based on the size of their shareholding:

Divi (Satchandra Kiran) Individual Investor
Percentage owned: 20.34% (54.0m shares)
Motaparti (Nilima) Individual Investor
Percentage owned: 20.34% (54.0m shares)
Divi (Swarna Latha) Individual Investor
Percentage owned: 5.27% (14.0m shares)
SBI Funds Management Pvt. Ltd. Investment Advisor
Percentage owned: 4.69% (12.5m shares)
Axis Asset Management Company Limited Investment Advisor
Percentage owned: 3.14% (8.34m shares)
Similar to DIVISLAB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.